RE-VOLUTION: The RE-SOLVE study. Dabigatran etexilate in the secondary prevention of venous thromboembolism
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms RE-SOLVE
- Sponsors Boehringer Ingelheim
- 17 Dec 2012 Status changed to recruiting.
- 31 Jan 2006 New trial record.